STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person
   Kewalramani Reshma
   C/O VERTEX PHARMACEUTICALS INC
   50 NORTHERN AVENUE
   BOSTON MA 02210

2. Issuer Name and Ticker or Trading Symbol
   VERTEX PHARMACEUTICALS INC / MA [VRTX]

3. Date of Earliest Transaction (Month/Day/Year)
   12/15/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)
   02/05/2028

5. Relationship of Reporting Person(s) to Issuer
   X Director 10% Owner
   X Officer (give title below) CEO & President
   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication
   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

** Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned **

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Code</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>12/15/2023</td>
<td>M</td>
<td>3,058</td>
<td>$155.57</td>
</tr>
<tr>
<td>Common Stock</td>
<td>12/15/2023</td>
<td>M</td>
<td>14,077</td>
<td>$187.53</td>
</tr>
<tr>
<td>Common Stock</td>
<td>12/15/2023</td>
<td>M</td>
<td>17,135</td>
<td>$407</td>
</tr>
</tbody>
</table>

** Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) **

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Code</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$155.57</td>
<td>12/15/2023</td>
<td>M</td>
<td>3,058</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$187.53</td>
<td>12/15/2023</td>
<td>M</td>
<td>14,077</td>
</tr>
</tbody>
</table>

** Explanation of Responses: **

1. Transaction made pursuant to Dr. Kewalramani’s company-approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.
2. Fully vested.

** Remarks: **

A: Christiana Stevenson, Attorney-in-Fact

Date 12/19/2023

** Signature of Reporting Person **

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.